Aileron Therapeutics (ALRN)
(Delayed Data from NSDQ)
$2.42 USD
-0.03 (-1.22%)
Updated Aug 27, 2024 04:00 PM ET
After-Market: $2.42 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for Aileron Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -15.73 | -27.33 | -26.16 | -21.16 | -29.37 |
Depreciation/Amortization & Depletion | 0.15 | -0.04 | 0.36 | 0.15 | -0.08 |
Net Change from Assets/Liabilities | -5.38 | 0.42 | 0.24 | -1.28 | 0.85 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 1.15 | 2.08 | 1.81 | 1.81 | 2.12 |
Net Cash From Operating Activities | -19.81 | -24.87 | -23.75 | -20.48 | -26.47 |
Property & Equipment | 0.04 | 0.00 | -0.09 | 0.20 | -0.15 |
Acquisition/ Disposition of Subsidiaries | -0.10 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 16.25 | 26.46 | -35.83 | 6.21 | -2.66 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 16.20 | 26.46 | -35.92 | 6.41 | -2.81 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.00 | 0.00 | 55.66 | 15.41 | 23.96 |
Issuance (Repayment) of Debt | 15.79 | 0.00 | 0.00 | 0.39 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 15.79 | 0.00 | 55.66 | 15.80 | 23.96 |
Effect of Exchange Rate Changes | -0.06 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 12.12 | 1.59 | -4.01 | 1.74 | -5.32 |
Cash at Beginning of Period | 5.22 | 3.63 | 7.64 | 5.90 | 11.23 |
Cash at End of Period | 17.34 | 5.22 | 3.63 | 7.64 | 5.90 |
Diluted Net EPS | -3.42 | -6.02 | -5.80 | -12.20 | -24.00 |
Fiscal Year End for Aileron Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -16.06 | -7.11 | -15.73 | -8.39 | -6.57 |
Depreciation/Amortization & Depletion | 0.06 | 0.06 | 0.15 | -0.09 | -0.10 |
Net Change from Assets/Liabilities | 1.86 | 1.63 | -5.38 | -1.83 | -1.82 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 0.48 | 0.15 | 1.15 | 0.89 | 0.71 |
Net Cash From Operating Activities | -13.66 | -5.27 | -19.81 | -9.42 | -7.78 |
Property & Equipment | 0.00 | 0.00 | 0.04 | 0.04 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | -0.10 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 16.25 | 16.25 | 15.75 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 0.00 | 0.00 | 16.20 | 16.29 | 15.75 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 18.26 | 0.00 | 0.00 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 15.79 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 18.26 | 0.00 | 15.79 | 0.00 | 0.00 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | -0.06 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 4.60 | -5.27 | 12.12 | 6.88 | 7.97 |
Cash at Beginning of Period | 17.34 | 17.34 | 5.22 | 5.22 | 5.22 |
Cash at End of Period | 21.94 | 12.07 | 17.34 | 12.09 | 13.19 |
Diluted Net EPS | -0.45 | -0.86 | -1.58 | -0.40 | -0.39 |